Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1α pathway

PLoS One. 2012;7(12):e53152. doi: 10.1371/journal.pone.0053152. Epub 2012 Dec 31.

Abstract

We had demonstrated that plasminogen kringle 5 (K5), a potent angiogenic inhibitor, inhibited retinal neovascularization and hepatocellular carcinoma growth by anti-angiogenesis. The current study investigated the effects and the underlying mechanisms of K5 on both tumor growth and spontaneous pulmonary metastasis in Lewis lung carcinoma (LLC) implanted mouse model. Similarly, K5 could decrease expression of VEGF in LLC cells and grafted tissues and suppress tumor angiogenesis and growth. K5 had no direct effect on proliferation and apoptosis of LLC. However, K5 could significantly inhibit SDF-1α-induced chemotaxis movement of LLC cells and resulted in a great reduction of surface metastatic nodules and micrometastases in the lungs of LLC tumor-bearing mice. K5 also decreased expression of chemokine (C-X-C motif) receptor 4 (CXCR4) in LLC cells and grafted tissues. Furthermore, K5 down-regulated SDF-1α expression in metastatic lung tissues of LLC-bearing mice. Therefore, K5 may suppress tumor pulmonary metastasis through inhibiting SDF-1α-CXCR4 chemotaxis movement and down-regulation of VEGF. Moreover, the role of hypoxia inducible factor-1α (HIF-1α), a crucial transcriptional factor for both VEGF and CXCR4 expression, was evaluated. The siRNA of HIF-1α attenuated expression of VEGF and CXCR4 and inhibited LLC migration. K5 decreased HIF-1α protein level and impaired nuclear HIF-1α accumulation. These results showed for the first time that K5 inhibits LLC growth and metastasis via the dual effects of anti-angiogenesis and suppression of tumor cell motility by targeting the pivotal molecule, HIF-1α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Apoptosis / drug effects
  • Carcinoma, Lewis Lung / metabolism*
  • Carcinoma, Lewis Lung / pathology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Chemokine CXCL12 / metabolism
  • Chemotaxis / drug effects*
  • Down-Regulation / drug effects
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Mice
  • Neoplasm Transplantation
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / metabolism*
  • Neovascularization, Pathologic / pathology
  • Peptide Fragments / pharmacology*
  • Peptide Fragments / therapeutic use
  • Plasminogen / pharmacology*
  • Plasminogen / therapeutic use
  • Signal Transduction / drug effects*
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiogenesis Inhibitors
  • Chemokine CXCL12
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Peptide Fragments
  • Vascular Endothelial Growth Factor A
  • plasminogen kringle 5
  • Plasminogen

Grants and funding

This work was supported by National Nature Science Foundation of China (30700120, 30971208, 30973449, 81070746, 81071893, 81172163, 81272515, 81272338 and 81272553), National Key Sci-Tech Special Project of China (2009ZX09103-642 and 2013ZX09102-053), Program for Doctoral Station in University (20070558215, 108104, 20100171110049), Guandong natural science foundation (10151008901000007, S2012020010898 and Key Project 10251008901000009), Fundamental Research Funds for the Central Universities of China (Youth Program 09YKPY73, 10YKPY28), Changjiang Scholars and Innovative Research Team in University (985 project PCSIRT 0947), and Guangzhou Science and Technology Project (2011J4100106, 2011Y1-00017-8). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.